Study wrapper · #977
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
Davies MJ, Bajaj HS, Broholm C, et al. The New England journal of medicine. 2025.
DOI: 10.1056/nejmoa2502082PubMed: 40544432
Editor's note
The REDEFINE 2 phase 3a trial (1206 participants, 68 weeks) in adults with type 2 diabetes reporting a mean weight change of -13.7% with cagrilintide-semaglutide versus -3.4% with placebo, plus substantial improvements in glycated hemoglobin. Gastrointestinal adverse events were common but mostly mild-to-moderate. High-quality primary human evidence on both tracked peptides.
Plain-language abstract
In this phase 3 trial in adults with type 2 diabetes, cagrilintide-semaglutide was associated with about 14% weight loss versus 3% with placebo, alongside improved glucose control.
Related coverage
Mixed
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Lancet (London, England)n=——2026
Supported
Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding.
Physiology & behaviorn=——2026
Supported
Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.
Naunyn-Schmiedeberg's archives of pharmacologyn=——2026